StockNews.AI
VTRS
StockNews.AI
159 days

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

1. Faruqi & Faruqi investigates potential claims against Viatris. 2. Viatris reported Q4 2024 results missing estimates and lower 2025 guidance. 3. Their stock fell 15.21% to $9.53 after the announcement. 4. Remediation efforts at an Indian facility are ongoing with FDA updates. 5. Investors suffering losses are encouraged to explore legal options.

5m saved
Insight
Article

FAQ

Why Bearish?

VTRS missed earnings estimates, leading to a significant stock drop, indicating ongoing market concerns.

How important is it?

The article directly addresses legal investigations following poor financial performance, affecting investor confidence.

Why Short Term?

Immediate investor sentiment is negative due to poor earnings and guidance; future outlook may stabilize post-remediation.

Related Companies

Mylan N.V.PFEBMY
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information], /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS).Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP) On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was "more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility."  On this news, Viatris's stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025.To learn more about the Viatris Inc. investigation, go to www.faruqilaw.com/VTRS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.SOURCE Faruqi & Faruqi, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News